Annual CFO
-$31.84 M
+$3.16 M+9.02%
December 31, 2022
Summary
- As of February 8, 2025, ELOX annual cash flow from operations is -$31.84 million, with the most recent change of +$3.16 million (+9.02%) on December 31, 2022.
- During the last 3 years, ELOX annual CFO has risen by +$7.55 million (+19.16%).
Performance
ELOX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$3.45 M
-$1.38 M-66.99%
September 30, 2023
Summary
- As of February 8, 2025, ELOX quarterly cash flow from operations is -$3.45 million, with the most recent change of -$1.38 million (-66.99%) on September 30, 2023.
- Over the past year, ELOX quarterly CFO has increased by +$3.50 million (+50.33%).
- ELOX quarterly CFO is now -45494.74% below its all-time high of $7600.00, reached on September 30, 2007.
Performance
ELOX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$17.99 M
+$3.50 M+16.27%
September 30, 2023
Summary
- As of February 8, 2025, ELOX TTM cash flow from operations is -$17.99 million, with the most recent change of +$3.50 million (+16.27%) on September 30, 2023.
- Over the past year, ELOX TTM CFO has increased by +$18.12 million (+50.18%).
- ELOX TTM CFO is now -4121.26% below its all-time high of -$426.20 thousand, reached on September 30, 2000.
Performance
ELOX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ELOX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +9.0% | +50.3% | +50.2% |
| 3 y3 years | +19.2% | +34.4% | +45.1% |
| 5 y5 years | -99.8% | +61.9% | +54.3% |
ELOX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +9.0% | -67.0% | +65.3% | at high | +51.1% |
| 5 y | 5-year | -13.1% | +19.2% | -67.0% | +71.1% | at high | +57.3% |
| alltime | all time | <-9999.0% | +19.2% | <-9999.0% | +71.1% | -4121.3% | +57.3% |
Eloxx Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$3.45 M(+67.0%) | -$17.99 M(-16.3%) |
| Jun 2023 | - | -$2.07 M(-69.7%) | -$21.49 M(-26.3%) |
| Mar 2023 | - | -$6.81 M(+20.4%) | -$29.17 M(-8.4%) |
| Dec 2022 | -$31.84 M(-9.0%) | -$5.66 M(-18.5%) | -$31.84 M(-11.8%) |
| Sep 2022 | - | -$6.95 M(-28.7%) | -$36.12 M(-1.7%) |
| Jun 2022 | - | -$9.75 M(+2.7%) | -$36.76 M(-0.1%) |
| Mar 2022 | - | -$9.49 M(-4.4%) | -$36.81 M(+5.2%) |
| Dec 2021 | -$35.00 M(+24.3%) | -$9.93 M(+30.9%) | -$35.00 M(+17.7%) |
| Sep 2021 | - | -$7.59 M(-22.5%) | -$29.74 M(+8.5%) |
| Jun 2021 | - | -$9.80 M(+27.5%) | -$27.41 M(+14.5%) |
| Mar 2021 | - | -$7.68 M(+64.6%) | -$23.93 M(-15.1%) |
| Dec 2020 | -$28.17 M(-28.5%) | -$4.67 M(-11.2%) | -$28.17 M(-14.0%) |
| Sep 2020 | - | -$5.26 M(-16.8%) | -$32.76 M(-15.6%) |
| Jun 2020 | - | -$6.32 M(-47.0%) | -$38.82 M(-7.9%) |
| Mar 2020 | - | -$11.92 M(+28.8%) | -$42.13 M(+6.9%) |
| Dec 2019 | -$39.39 M(+25.6%) | -$9.26 M(-18.2%) | -$39.39 M(+0.5%) |
| Sep 2019 | - | -$11.32 M(+17.6%) | -$39.19 M(+9.0%) |
| Jun 2019 | - | -$9.62 M(+4.7%) | -$35.97 M(+3.2%) |
| Mar 2019 | - | -$9.19 M(+1.4%) | -$34.86 M(+11.1%) |
| Dec 2018 | -$31.37 M(+96.8%) | -$9.06 M(+11.9%) | -$31.37 M(+40.6%) |
| Sep 2018 | - | -$8.10 M(-4.8%) | -$22.31 M(+50.9%) |
| Jun 2018 | - | -$8.51 M(+49.4%) | -$14.78 M(+118.0%) |
| Mar 2018 | - | -$5.70 M(+890.3%) | -$6.78 M(+252.0%) |
| Dec 2017 | -$15.94 M(+727.7%) | - | - |
| Sep 2017 | - | -$575.30 K(+13.1%) | -$1.93 M(+0.1%) |
| Jun 2017 | - | -$508.80 K(+25.7%) | -$1.93 M(-9.7%) |
| Jun 2017 | -$1.93 M(-47.6%) | - | - |
| Mar 2017 | - | -$404.70 K(-7.6%) | -$2.13 M(-17.0%) |
| Dec 2016 | - | -$437.90 K(-23.7%) | -$2.57 M(-17.7%) |
| Sep 2016 | - | -$573.70 K(-19.7%) | -$3.12 M(-15.2%) |
| Jun 2016 | -$3.68 M(-49.9%) | -$714.80 K(-15.0%) | -$3.68 M(-31.7%) |
| Mar 2016 | - | -$841.00 K(-14.9%) | -$5.38 M(-10.2%) |
| Dec 2015 | - | -$988.30 K(-12.7%) | -$5.99 M(-8.3%) |
| Sep 2015 | - | -$1.13 M(-53.2%) | -$6.54 M(-11.0%) |
| Jun 2015 | -$7.34 M(+50.9%) | -$2.42 M(+66.8%) | -$7.34 M(+19.6%) |
| Mar 2015 | - | -$1.45 M(-5.3%) | -$6.14 M(-1.7%) |
| Dec 2014 | - | -$1.53 M(-20.9%) | -$6.25 M(+1.8%) |
| Sep 2014 | - | -$1.94 M(+59.2%) | -$6.14 M(+26.1%) |
| Jun 2014 | -$4.87 M(+24.7%) | -$1.22 M(-21.8%) | -$4.87 M(+5.9%) |
| Mar 2014 | - | -$1.56 M(+9.5%) | -$4.60 M(-4.1%) |
| Dec 2013 | - | -$1.42 M(+112.1%) | -$4.79 M(+21.8%) |
| Sep 2013 | - | -$670.50 K(-29.1%) | -$3.94 M(+0.9%) |
| Jun 2013 | -$3.90 M(-11.0%) | -$946.30 K(-46.1%) | -$3.90 M(-4.0%) |
| Mar 2013 | - | -$1.75 M(+210.3%) | -$4.06 M(+23.5%) |
| Dec 2012 | - | -$565.40 K(-11.2%) | -$3.29 M(-16.3%) |
| Sep 2012 | - | -$636.50 K(-42.6%) | -$3.93 M(-10.3%) |
| Jun 2012 | -$4.39 M | -$1.11 M(+13.1%) | -$4.39 M(+2.0%) |
| Mar 2012 | - | -$980.00 K(-18.8%) | -$4.30 M(-6.7%) |
| Dec 2011 | - | -$1.21 M(+10.8%) | -$4.61 M(-5.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2011 | - | -$1.09 M(+6.5%) | -$4.88 M(-9.6%) |
| Jun 2011 | -$5.39 M(+13.7%) | -$1.02 M(-20.7%) | -$5.39 M(-23.1%) |
| Mar 2011 | - | -$1.29 M(-12.4%) | -$7.01 M(+12.2%) |
| Dec 2010 | - | -$1.47 M(-8.3%) | -$6.25 M(+17.9%) |
| Sep 2010 | - | -$1.61 M(-39.2%) | -$5.30 M(+11.7%) |
| Jun 2010 | -$4.74 M(+19.7%) | -$2.64 M(+401.0%) | -$4.74 M(+55.0%) |
| Mar 2010 | - | -$527.20 K(+0.2%) | -$3.06 M(-8.1%) |
| Dec 2009 | - | -$526.00 K(-49.8%) | -$3.33 M(-14.6%) |
| Sep 2009 | - | -$1.05 M(+9.5%) | -$3.90 M(-1.6%) |
| Jun 2009 | -$3.96 M(+64.7%) | -$957.70 K(+20.0%) | -$3.96 M(+2.5%) |
| Mar 2009 | - | -$798.00 K(-27.2%) | -$3.86 M(-2.1%) |
| Dec 2008 | - | -$1.10 M(-1.4%) | -$3.95 M(+12.0%) |
| Sep 2008 | - | -$1.11 M(+29.3%) | -$3.52 M(+46.5%) |
| Jun 2008 | -$2.41 M(+18.4%) | -$859.70 K(-2.3%) | -$2.41 M(+20.5%) |
| Mar 2008 | - | -$879.60 K(+30.6%) | -$2.00 M(+12.6%) |
| Dec 2007 | - | -$673.70 K(-8964.5%) | -$1.77 M(+1.2%) |
| Sep 2007 | - | $7600.00(-101.7%) | -$1.75 M(-13.7%) |
| Jun 2007 | -$2.03 M(-19.7%) | -$450.10 K(-31.5%) | -$2.03 M(-23.8%) |
| Mar 2007 | - | -$656.90 K(+0.5%) | -$2.67 M(+15.0%) |
| Dec 2006 | - | -$653.40 K(+141.0%) | -$2.32 M(+5.8%) |
| Sep 2006 | - | -$271.10 K(-75.0%) | -$2.19 M(-13.3%) |
| Jun 2006 | -$2.53 M(+19.6%) | -$1.09 M(+251.9%) | -$2.53 M(+23.9%) |
| Mar 2006 | - | -$308.60 K(-41.4%) | -$2.04 M(-16.9%) |
| Dec 2005 | - | -$527.00 K(-13.4%) | -$2.46 M(+10.5%) |
| Sep 2005 | - | -$608.80 K(+1.9%) | -$2.22 M(+5.1%) |
| Jun 2005 | -$2.12 M(+11.8%) | -$597.70 K(-17.3%) | -$2.12 M(-1.3%) |
| Mar 2005 | - | -$722.50 K(+145.9%) | -$2.14 M(+17.7%) |
| Dec 2004 | - | -$293.80 K(-41.5%) | -$1.82 M(-7.3%) |
| Sep 2004 | - | -$501.80 K(-19.9%) | -$1.96 M(+3.7%) |
| Jun 2004 | -$1.89 M(-5.4%) | -$626.30 K(+56.8%) | -$1.89 M(+2.1%) |
| Mar 2004 | - | -$399.40 K(-8.5%) | -$1.86 M(+1.6%) |
| Dec 2003 | - | -$436.30 K(+1.1%) | -$1.83 M(-5.1%) |
| Sep 2003 | - | -$431.40 K(-26.6%) | -$1.92 M(-3.9%) |
| Jun 2003 | -$2.00 M(+52.6%) | -$588.00 K(+58.6%) | -$2.00 M(+14.3%) |
| Mar 2003 | - | -$370.70 K(-30.6%) | -$1.75 M(-10.3%) |
| Dec 2002 | - | -$534.30 K(+4.9%) | -$1.95 M(+31.6%) |
| Sep 2002 | - | -$509.50 K(+50.8%) | -$1.49 M(+13.1%) |
| Jun 2002 | -$1.31 M(-11.5%) | -$337.90 K(-40.9%) | -$1.31 M(+4.0%) |
| Mar 2002 | - | -$572.20 K(+772.3%) | -$1.26 M(+26.2%) |
| Dec 2001 | - | -$65.60 K(-80.5%) | -$1.00 M(-28.3%) |
| Sep 2001 | - | -$336.90 K(+17.2%) | -$1.39 M(-6.0%) |
| Jun 2001 | -$1.48 M(-17.9%) | -$287.50 K(-7.3%) | -$1.48 M(+24.0%) |
| Mar 2001 | - | -$310.30 K(-32.5%) | -$1.20 M(+35.0%) |
| Dec 2000 | - | -$459.80 K(+7.9%) | -$886.00 K(+107.9%) |
| Sep 2000 | - | -$426.20 K | -$426.20 K |
| Jun 2000 | -$1.81 M(+85.5%) | - | - |
| Jun 1999 | -$973.80 K(<-9900.0%) | - | - |
| Jun 1998 | $0.00(0.0%) | - | - |
| Jun 1997 | $0.00 | - | - |
FAQ
- What is Eloxx Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Eloxx Pharmaceuticals?
- What is Eloxx Pharmaceuticals annual CFO year-on-year change?
- What is Eloxx Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Eloxx Pharmaceuticals?
- What is Eloxx Pharmaceuticals quarterly CFO year-on-year change?
- What is Eloxx Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Eloxx Pharmaceuticals?
- What is Eloxx Pharmaceuticals TTM CFO year-on-year change?
What is Eloxx Pharmaceuticals annual cash flow from operations?
The current annual CFO of ELOX is -$31.84 M
What is the all time high annual CFO for Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals all-time high annual cash flow from operations is $0.00
What is Eloxx Pharmaceuticals annual CFO year-on-year change?
Over the past year, ELOX annual cash flow from operations has changed by +$3.16 M (+9.02%)
What is Eloxx Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ELOX is -$3.45 M
What is the all time high quarterly CFO for Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals all-time high quarterly cash flow from operations is $7600.00
What is Eloxx Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, ELOX quarterly cash flow from operations has changed by +$3.50 M (+50.33%)
What is Eloxx Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ELOX is -$17.99 M
What is the all time high TTM CFO for Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals all-time high TTM cash flow from operations is -$426.20 K
What is Eloxx Pharmaceuticals TTM CFO year-on-year change?
Over the past year, ELOX TTM cash flow from operations has changed by +$18.12 M (+50.18%)